Articles tagged with Chemotherapy
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Researchers found that a paclitaxel combination improved median and long-term survival rates for patients with early-stage SCLC. The treatment also reduced side effects compared to standard chemotherapy.
A new gene expression profile test could identify which breast cancer patients are likely to respond to chemotherapy, helping reduce unproductive treatment and toxicity. The test uses biopsy samples from primary tumors before treatment and measures the tumor's response to docetaxel.
Combining herbal supplements with regular medication without consulting a doctor can lead to adverse interactions. Patients should discuss their herbal supplement use with their primary physician to ensure safe treatment and prevent unexpected complications.
A Canadian-led study found that about 83% of colon cancer patients benefit from traditional chemotherapy, while nearly 17% do not. Further research is needed to provide alternative treatments for those who don't respond to standard therapy.
A Phase III trial found that pemetrexed and cisplatin significantly improved one-year survival rates for mesothelioma patients to 56.5%, compared to 41.9% for those receiving only cisplatin.
CYC202 demonstrates significant cancer cell death, with 54% of patients testing positive for apoptosis following single agent treatment. Seven patients experienced long-lasting tumour stabilisation in Phase I trials, showcasing potential for selective treatment based on genetic profiles.
Researchers have developed novel compounds that significantly improve anti-cancer therapy outcomes. The AvastinTM clinical trial shows that bevacizumab, an anti-angiogenesis agent, can slow or stop tumor growth and increase patient survival when combined with chemotherapy.
A national study found that 43% of patients reported nausea on the day of treatment, and 73% experienced nausea one or more days later. Delayed nausea is a significant problem, affecting twice as many patients who felt ill in the following days compared to those who felt queasy initially.
A recent study found that high-dose chemotherapy followed by autologous stem cell transplant did not significantly increase survival rates for women with early stage breast cancer. The study, which included 511 patients, showed a higher number of relapses in the treatment group but also nine deaths due to transplantation complications....
A randomized clinical trial of over 500 women with primary breast cancer found no significant improvement in disease-free survival or overall survival with high-dose chemotherapy and stem cell transplantation. However, time to recurrence was longer for patients who received the treatment.
Women treated with radiation therapy and chemotherapy had a 61% lower risk of developing breast cancer compared to those who received only radiation. The authors suggest that ovarian hormones play a role in promoting tumor growth after radiation, which may explain the increased breast cancer risk in young women exposed to radiation.
A phase 2 clinical trial found that bortezomib responded positively in 193 relapsed patients, including seven with undetectable myeloma protein and 12 with detectable protein only with immunofixation. The results confirmed significant clinical benefits from therapy.
Researchers at St. Jude Children's Hospital have successfully treated four pediatric patients with retinoblastoma using a combination of chemotherapy, radiation therapy, and stem-cell transplantation. The study shows promising results, with two out of four patients surviving for over six years without disease recurrence.
A study by Te Velde found that the Pringle manoeuvre increases tumour growth and recurrence after liver surgery, reducing patient survival chances. Medicines preventing blood vessel regeneration can be combined with chemotherapy to control tumours.
Contrast-enhanced MRI is a reliable method to measure blood flow to tumors, allowing for accurate assessment of chemotherapy response and tumor viability. The study found that patients who responded to treatment had significant decreases in angiogenesis, while non-responders showed increases.
Researchers found that patients with a negative pretransplantation scan had a favorable outcome, with 25 still in complete remission after a median follow-up of 1,510 days. In contrast, patients with a positive scan relapsed more frequently, highlighting the potential for [F]FDG-PET to identify nonresponders.
A study by Dr. Pio and colleagues found that FLT-PET imaging outperforms FDG-PET in predicting tumor response to chemotherapy in breast cancer patients. The researchers compared the two imaging modalities in 11 newly diagnosed patients, taking scans before treatment began, after the first dose, and following the final cycle.
Pregnant women should undergo thorough breast examinations to detect breast cancer, as diagnosis is often delayed due to hormonal changes. Ultrasonography is the best method for detecting cancerous lumps during pregnancy.
A study of 800 women with relapsing ovarian cancer found that combination chemotherapy showed a modest survival benefit compared to platinum-based chemotherapy alone. Women assigned combination therapy survived for an average of five months more than those given platinum therapy.
Chemoembolization is the treatment of choice for widespread or diffuse tumors, enabling patients with primary liver cancer to live longer and maintain a quality of life. The procedure uses oil droplets to transport chemotherapy agents directly to the tumor, reducing toxicity and improving outcomes.
Susan Bane's research focuses on understanding how anticancer drugs like Taxol interact with tubulin at the molecular level. The study of these interactions could pave the way for the development of more effective next-generation cancer drugs, potentially with improved administration and reduced resistance.
The study found that BAC proliferation correlated with HER2 but not EGFR expression, suggesting a potential role for combination therapies. Researchers hope to launch a clinical trial of HER2- and EGFR-blocker combination therapy in the treatment of BAC.
A new monoclonal antibody combination therapy has been found to be highly effective in treating chronic lymphocytic leukemia, with a remarkable 69% complete remission rate. The treatment, which combines two chemotherapy drugs with Rituximab, shows promising results across all age groups and stages of the disease.
Two studies found that paclitaxel-based chemotherapy regimens and mini-transplants can help preserve ovarian function in younger patients. The paclitaxel regimen improved a woman's chance of regaining her ovarian function, while mini-transplants showed better results in preserving ovaries compared to high-dose chemo.
A new study found that chemotherapy and radiotherapy together reduce surgery and removal of the voice box due to cancer recurrence. The combination treatment was associated with a significantly lower rate of surgeries compared to standard therapy or radiotherapy alone.
A new chemotherapy regimen combining docetaxel with cisplatin and 5-Fluorouracil has been shown to significantly improve survival rates in late-stage stomach cancer patients. The study found a nearly 80% higher chance of tumor shrinkage and a reduced risk of cancer growth.
Bevacizumab significantly extends survival time for metastatic colorectal cancer patients by shrinking tumors and inhibiting tumor growth. The study showed a median survival increase of five months compared to standard chemotherapy alone, with significant delays in cancer progression.
Researchers at Stanford have shown positive results with a new chemotherapy combination, Iressa and FOLFOX, in treating colon cancer. The treatment has been effective in shrinking tumors by up to 75% in patients who had never received chemotherapy before.
A new DNA array technology test has identified differences in gene patterns that predict which breast cancer patients will respond to chemotherapy. The study, led by Dr. Jenny Chang at Baylor College of Medicine, found that 88% of genes were correctly classified, allowing for personalized treatment strategies.
The GELA study reveals that MabThera plus CHOP improves three-year event-free survival by 18% and overall survival by 11%, with no increased toxicity. This breakthrough treatment offers a potential cure for aggressive NHL, which affects 55% of the 1.5 million people worldwide suffering from non-Hodgkin's lymphoma.
Researchers found that gefitinib can slow lung cancer tumor recurrence when used as maintenance therapy following chemotherapy. The study suggests that gefitinib may keep cancer cells dormant for a period of time.
Researchers at Memorial Sloan Kettering Cancer Center found that targeted therapy erlotinib caused dramatic tumor regressions in some patients with BAC, particularly those who never smoked. The treatment was effective in 25% of patients with advanced BAC, offering a new approach to managing this disease.
A new radiotherapy strategy, hyperfractionated accelerated radiotherapy (HART), has been shown to improve survival rates for lung cancer patients. In a phase III multi-site study, chemotherapy followed by HART resulted in a median survival of 21 months, compared to 12 months with standard radiation therapy.
Researchers at M. D. Anderson Cancer Center found that combining Gleevec with chemotherapy resulted in significant drops in PSA levels in some patients, indicating potential therapeutic benefit. The combination therapy showed slow but sustained responses, suggesting a valid target in prostate cancer treatment.
Researchers at the University of Texas M. D. Anderson Cancer Center have developed a gene screen that can accurately predict which chemotherapy regimens will be effective for patients with newly diagnosed breast cancer. The test is 75% accurate in forecasting complete eradication of cancer, eliminating the need for trial and error.
A Phase II study shows that administering ADVEXIN, a p53 drug, directly to tumors can improve the results of neoadjuvant chemotherapy in locally advanced breast cancer. The treatment resulted in dramatic tumor shrinkage and minimal residual tumor cells.
USC researchers have identified a protein fragment, PEP, that can increase the effectiveness of chemotherapy drugs against tumors. By making tumor blood vessels more permeable, PEP allows for better drug uptake and increased chemotherapy efficacy.
Researchers discover that ovarian tumor cells can 'switch back' to a normal state, making them vulnerable to chemotherapy. This finding represents a crucial step toward the discovery of new anti-cancer drugs.
Researchers treated 18 patients with lung nodules using radiofrequency ablation, achieving a 97% destruction rate. The treatment was found to be short-lasting and manageable, with most complications resolved within a week.
A Phase II study found that the DVd regimen showed a high response rate of 88%, with 12% achieving complete response. The treatment was well-tolerated, with the most common Grade 3 or 4 toxicity being palmar-plantar erythrodysesthesia. Improved patient education and prevention measures reduced toxicity incidence.
Researchers at McGill University discovered a genetic mutation, MTHFR variant, that predicts better response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer patients. The study found 26 out of 43 patients with the variant responded well to chemotherapy.
Researchers at Cedars-Sinai Medical Center found that patients with hereditary BRCA-associated ovarian cancer respond better to chemotherapy, leading to improved survival. The study suggests that platinum-based chemotherapy may be more effective for these patients, and this finding may enable physicians to better plan treatment.
Researchers identified 124 genes whose changes in expression differed depending on the treatment regimen, providing new clues on how medications work and how cancer cells protect themselves. The study's findings will help design more rational and effective ways to use drugs for deadly childhood leukemia.
Researchers found that ovarian cancer cells produce collagen VI, which remodels their environment to make them more resistant to chemotherapy. This could lead to new therapeutic interventions to overcome chemotherapy resistance and improve survival rates for women with ovarian cancer.
The article discusses the relationship between natural and synthetic substances in relation to human health. Key findings include the difficulty of synthesizing complex natural compounds and the potential for modification by synthetic chemists to enhance medicinal properties.
A new study found that strengthening upper leg muscles does not protect against knee osteoarthritis and may even worsen it in people with certain knee conditions. Researchers also discovered that one-third of cancer patients who died received chemotherapy in their last six months of life.
Researchers at M.D. Anderson Cancer Center found that the novel proteasome inhibitor PS-341 works synergistically with certain chemotherapy agents but not others, suggesting a critical role of sequence in treatment efficacy. The findings have important implications for future clinical trials and potential cancer treatments.
Researchers at Mayo Clinic have discovered that thalidomide can effectively delay the progression of early-stage multiple myeloma in some patients. In a phase II clinical trial, approximately 80% of patients remained progression-free after one year and 63% were still free from disease progression after two years.
According to a study by the National Cancer Institute, approximately 10 million women in the US aged 35-79 are eligible for tamoxifen due to high breast cancer risk. After analyzing age-related benefits and risks, researchers found that younger women (40-59) have a higher likelihood of benefiting from the drug.
Researchers have developed a novel screening technique that quickly identifies chemical compounds active only against certain cancer-causing genes and proteins. This approach opens the door to custom-tailoring chemotherapy and may lead to more effective treatments for specific types of cancer.
A new study led by Queen's University aims to increase the sensitivity of prostate cancers to anti-cancer drugs using nitroglycerine. Researchers hope to develop a better understanding of how prostate cancer cells become resistant to chemotherapy, with potential applications for other cancers such as breast cancer.
A Phase III randomized trial found that a combination of vinorelbine and gemcitabine did not improve overall and progression-free survival in elderly NSCLC patients. However, the study suggests that certain chemotherapy combinations, particularly cisplatin-based regimens, may be more effective than single-agent therapy. The results als...
Researchers have discovered a new six-drug chemotherapy regimen that significantly improves the overall survival rate of Ewing's sarcoma patients to 72% without metastases. The treatment has become routine care for patients with localized disease and has marked a substantial improvement in survival rates.
Researchers are working towards individualized treatments using DNA chip technology to analyze gene expression and detect host genetic polymorphisms. This approach aims to optimize drug selection and doses at a molecular level, reducing toxicity and improving patient outcomes for childhood acute lymphoblastic leukemia.
A new treatment, interleukin-11 (IL-11), has shown early promise in reducing the risk of infection in patients undergoing chemotherapy for blood cancer. Patients who received IL-11 experienced significantly fewer cases of bacterial infections compared to those who received a placebo.
The study found a significant discrepancy between recommended adjuvant chemotherapy and actual use, with younger women more likely to receive treatment. Overall, only 29% of women received chemotherapy, highlighting the need for re-evaluation of current NIH guidelines.
A study on breast cancer treatment found that many women do not receive adjuvant chemotherapy as recommended, with age being a significant factor. In contrast, women with known heart disease are at high risk of future heart events but often lack preventive treatments, highlighting the need for better care coordination.
Two trials found that adjuvant chemotherapy improved recurrence-free survival by 8-11% and overall survival by 5-9%, primarily benefiting patients with unrecognized residual disease. These findings suggest that adjuvant chemotherapy may be most effective in patients with non-optimal surgical staging.
A novel treatment approach combining surgery and intraperitoneal hyperthermic chemotherapy (IPHC) has shown significant promise in improving survival rates for patients with peritoneal carcinomatosis. The study found that selected patients may benefit from improved quality of life and extended survival.
Researchers have discovered that combining Avastin with chemotherapy provides superior treatment for advanced colorectal cancer, increasing median survival by 8.3 months and response rates. The study's findings suggest a more effective and less toxic option for patients with this devastating form of cancer.